MicroRNAs as serum biomarkers in Becker muscular dystrophy

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Becker muscular dystrophy (BMD) is an X-linked neuromuscular disorder caused by DMD gene mutations, leading to progressive muscle degeneration.
• Dysregulated expression of muscle-specific microRNAs (myomirs) is observed in muscular dystrophies, but understudied in BMD.
• Existing research highlights the potential of circulating microRNAs as biomarkers in various diseases.

Purpose of the Study:

• To analyze serum expression levels of specific myomirs in individuals with Becker muscular dystrophy.
• To investigate the correlation between myomir levels, muscle biopsy findings, and clinical outcomes in BMD patients.
• To evaluate the potential of circulating myomirs as noninvasive biomarkers for BMD diagnosis and prognosis.

Main Methods:

• Serum samples were collected from 29 ambulant BMD patients and 11 healthy controls.
• Expression levels of a subset of myomirs (miR-1, miR-133a, miR-133b, miR-206) were quantified.
• BMD patients were classified based on muscle biopsy alterations and motor performance.

Main Results:

• Significant upregulation of serum miR-1, miR-133a, miR-133b, and miR-206 was observed in BMD patients compared to controls.
• Identified serum cut-off levels effectively discriminate BMD patients from healthy individuals.
• Serum miR-133b levels correlated with muscle fibrosis and motor performance, suggesting prognostic value.

Conclusions:

• Circulating myomirs (miR-1, miR-133a, miR-133b, miR-206) are promising noninvasive biomarkers for Becker muscular dystrophy.
• Serum myomir levels can aid in patient stratification, disease progression monitoring, and assessment of treatment efficacy.
• miR-133b may serve as a valuable prognostic marker for BMD patients, correlating with disease severity and clinical outcomes.